Category News

Saphnelo Self-Administration Meets Primary Endpoint in TULIP-SC Phase III Trial

Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus…

Read MoreSaphnelo Self-Administration Meets Primary Endpoint in TULIP-SC Phase III Trial

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

Pioneering sustainable transatlantic transport to cut emissions in pharmaceutical supply chains Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using…

Read MoreTakeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1,…

Read MoreThree WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

Cytokinetics Plans $550 Million Private Placement of Convertible Senior Notes

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes  Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due…

Read MoreCytokinetics Plans $550 Million Private Placement of Convertible Senior Notes

Cytokinetics Prices $650M Upsized Convertible Notes to Refinance 2027 Debt

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior…

Read MoreCytokinetics Prices $650M Upsized Convertible Notes to Refinance 2027 Debt

FDA grants Breakthrough Therapy status to Raludotatug Deruxtecan for CDH6+ ovarian cancers

FDA grants Breakthrough Therapy Designation to Raludotatug Deruxtecan for CDH6+ platinum-resistant ovarian and related cancers previously treated with bevacizumab Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment…

Read MoreFDA grants Breakthrough Therapy status to Raludotatug Deruxtecan for CDH6+ ovarian cancers

EU approves Novo Nordisk’s oral semaglutide—the first oral GLP-1 RA to cut cardiovascular risks

EU approves first oral GLP-1 RA to cut cardiovascular risk Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular…

Read MoreEU approves Novo Nordisk’s oral semaglutide—the first oral GLP-1 RA to cut cardiovascular risks